As another year comes to an end, five members of Ophthalmology Times Europe’s Editorial Advisory Board reflect and share their perspectives on the exciting opportunities that lie ahead for ophthalmologists in 2018, whilst also considering the potential challenges.
A combination of a topical corticosteroid and a nonsteroidal anti-inflammatory drug (NSAID) is more effective than either one alone in reducing the risk of cystoid macular oedema (CME) after cataract surgery in nondiabetic patients, researchers say.
A multidiagnostic device is able to provide consistent measurements of refraction and ocular aberrations in healthy eyes. The consistency of refractive measurements is not dependent on the magnitude of the refractive error, with the same precision ability for moderate to high myopia and for hyperopia.
Micropulse transscleral cyclophotocoagulation utilises a different delivery modality than its predecessor, continuous-wave laser cycloablation, to produce a biological reaction without the lethal effects caused by thermal buildup.
During the past two decades, an incredible number of imaging technologies have been developed for eye diseases, both for diagnosis and follow-up.
Long-term observation of SMILE reveals high stability at various degrees of correction of myopia. This allows surgeons who apply this method of treatment to give patients a long-term prognosis.
After spending a few months testing for dry eye and treating the tear film before doing preoperative measurements, the re-treatment rate dropped from 11% to 3%.
Children in Tel Aviv have been treated with nightly atropine drops, significantly slowing the progression of myopia.
One source of error in IOL power calculation is the use of the classical keratometric approach for the characterisation of the corneal optics. This approach is based on the assumption of only one corneal surface and a fictitious index of refraction (keratometric index, nk) for obtaining an estimation of the corneal power (Pk).
The European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.